Expanded Access to VAL-083
Primary Purpose
Cancer
Status
Available
Phase
Locations
Study Type
Expanded Access
Intervention
VAL-083
Sponsored by

About this trial
This is an expanded access trial for Cancer
Eligibility Criteria
Inclusion Criteria:
- Patient has relapsed/refractory disease and exhausted all standard treatments.
Exclusion Criteria:
- Patient is eligible for a VAL-083 clinical trial.
- Patient has previously received VAL-083 for the same disease.
Sites / Locations
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT03138629
First Posted
May 1, 2017
Last Updated
November 14, 2021
Sponsor
Kintara Therapeutics, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT03138629
Brief Title
Expanded Access to VAL-083
Official Title
Expanded Access to VAL-083
Study Type
Expanded Access
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Kintara Therapeutics, Inc.
4. Oversight
5. Study Description
Brief Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to VAL-083 (dianhydrogalactitol) prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
VAL-083
Intervention Description
VAL-083 will be administered intravenously
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Eligibility Criteria
Inclusion Criteria:
Patient has relapsed/refractory disease and exhausted all standard treatments.
Exclusion Criteria:
Patient is eligible for a VAL-083 clinical trial.
Patient has previously received VAL-083 for the same disease.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
John Langlands, Ph.D
Phone
(604) 629-5989
Email
jlanglands@kintara.com
12. IPD Sharing Statement
Learn more about this trial
Expanded Access to VAL-083
We'll reach out to this number within 24 hrs